CoChat

PIK3CA mutations confer resistance to first-line chemotherapy in colorectal cancer

Open access
Wang, Qiang, Shi, Yan-long, Zhou, Kai, Wang, Li-li, Yan, Ze-xuan, Liu, Yu-lin, Xu, Li-li, Zhao, Shi-wei, Chu, Hui-li, Shi, Ting-ting, Ma, Qing-hua, Bi, Jingwang · 2018 · Cell Death & Disease

The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.

Abstract

Chemotherapy represents an important treatment option for colorectal cancer (CRC), but only half of the patients benefit from these regimens. We explored the potential predicting value and mechanism of PIK3CA mutation in CRC chemotherapy. CRC specimens from 440 patients were retrospectively collected and examined with a fluorescence PCR-based method. The correlation of first-line chemotherapy response and PIK3CA mutation was evaluated according to follow-up and medical records. The underlying mechanism of PIK3CA mutation in chemotherapy resistance was assessed with CRC tumors and primary cells. The mutation frequency of the PIK3CA gene in CRC patients was 9.55%, which was correlated with late TNM staging and lower histological grade. The CRC patients with PIK3A mutation showed worse response to first-line chemotherapy than those without PIK3CA mutation. PIK3A mutation tumor cells showed poor sensitivity to first-line chemotherapy in vitro and in vivo. PIK3CA mutation induced PI3K/Akt signaling activation to increase LGR5 + CRC stem cells survival and proliferation, from which lead to chemotherapy resistance. Furthermore, PIK3CA mutation /LGR5 + expression was an independent detrimental factor for CRC patients. Our findings indicated that PIK3CA mutation induced PI3K/Akt activation contributed to CRC stem cells survival and proliferation, from which cells further resistance to chemotherapy. PIK3CA mutation /LGR5 + expression was a potential biomarker for monitoring chemotherapy resistance in CRC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41419-018-0776-6

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 The correlation between chemotherapy response and PIK3CA mutation status in CRC patients. a The percentage of PIK3CA mutation in the patients effective and non-effective to first-line chemotherapy. *p < 0.05. b Chemotherapy rsponses among patients with wild-type, PIK3CA mutant, exon 9 mutant and exon 20 mutant tumors
Fig. 1 The correlation between chemotherapy response and PIK3CA mutation status in CRC patients. a The percentage of PIK3CA mutation in the patients effective and non-effective to first-line chemotherapy. *p < 0.05. b Chemotherapy rsponses among patients with wild-type, PIK3CA mutant, exon 9 mutant and exon 20 mutant tumorsCC BY · PubMed Central
Fig. 2 PIK3CA mutation correlates with first-line chemotherapy resistance. a Western blot analysis of pAkt, Akt and GAPDH (loading control) in primary CRC cells. b CC-1 and CC-2 cells were incubated with 5-Fu (25 µM) for 72 h. Cell viability was examined by the MTT assay. Results represent the mean ± S.E.M. of the values relative to vehicle controls; *P < 0.05. c CC-1 cells were incubated combined perifosine or LY294002 with 5-FU. Cell viability was examined by the MTT assay. The data are shown as means ± S.E.M. d Immunoblots showing caspase-3 and GAPDH (loading control) expression levels in CC-1 cells treated with perifosine or LY294002 combined with 5-Fu (1 μM) for 24 h, and in CC-2 cells. e The colorectal cancer cells (CC-1) were treated with perifosine, LY294002 or 5-Fu for 48 h and the cells were collected for apoptosis analysis by flow cytometry (n = 3). f In vivo tumorigenicity of CRC xenograft tumors treated with or without perifosine. The tumor growth was monitored every week until 6 weeks after injection. Data are shown as means ± S.E.M. *P < 0.05
Fig. 2 PIK3CA mutation correlates with first-line chemotherapy resistance. a Western blot analysis of pAkt, Akt and GAPDH (loading control) in primary CRC cells. b CC-1 and CC-2 cells were incubated with 5-Fu (25 µM) for 72 h. Cell viability was examined by the MTT assay. Results represent the mean ± S.E.M. of the values relative to vehicle controls; *P < 0.05. c CC-1 cells were incubated combined perifosine or LY294002 with 5-FU. Cell viability was examined by the MTT assay. The data are shown as means ± S.E.M. d Immunoblots showing caspase-3 and GAPDH (loading control) expression levels in CC-1 cells treated with perifosine or LY294002 combined with 5-Fu (1 μM) for 24 h, and in CC-2 cells. e The colorectal cancer cells (CC-1) were treated with perifosine, LY294002 or 5-Fu for 48 h and the cells were collected for apoptosis analysis by flow cytometry (n = 3). f In vivo tumorigenicity of CRC xenograft tumors treated with or without perifosine. The tumor growth was monitored every week until 6 weeks after injection. Data are shown as means ± S.E.M. *P < 0.05CC BY · PubMed Central
Fig. 3 PIK3CA mutation related PI3K/Akt signaling increased CRC stem cell survival. a Quantitative analysis of primary and secondary sphere formation by CC-1 and CC-2 cells. b Quantitative analysis of sphere formation by CRC cells treated with perifosine or LY294002. c Flow cytometry analysis of LGR5 expression in CC-1 and CC-2 cells. d qRT-PCR analysis of stem cell markers, CD133, C-MYC, LGR5, ALDH1A1, NANOG and CXCR4 genes expression in CC-1 and CC-2. e Immunoblots showing p-Akt, Akt, LGR5, C-myc and GAPDH (loading control) expression levels in PIK3CA mutant tumor tissue comparing with that without mutation. f Immunoblots showing p-Akt, Akt, LGR5, C-myc and GAPDH (loading control) expression levels in CC-1 cells treated with perifosine, LY294002 or BpV (phen) comparing with vehicle
Fig. 3 PIK3CA mutation related PI3K/Akt signaling increased CRC stem cell survival. a Quantitative analysis of primary and secondary sphere formation by CC-1 and CC-2 cells. b Quantitative analysis of sphere formation by CRC cells treated with perifosine or LY294002. c Flow cytometry analysis of LGR5 expression in CC-1 and CC-2 cells. d qRT-PCR analysis of stem cell markers, CD133, C-MYC, LGR5, ALDH1A1, NANOG and CXCR4 genes expression in CC-1 and CC-2. e Immunoblots showing p-Akt, Akt, LGR5, C-myc and GAPDH (loading control) expression levels in PIK3CA mutant tumor tissue comparing with that without mutation. f Immunoblots showing p-Akt, Akt, LGR5, C-myc and GAPDH (loading control) expression levels in CC-1 cells treated with perifosine, LY294002 or BpV (phen) comparing with vehicleCC BY · PubMed Central
Fig. 4 The prognostic value of PIK3CA mutation and LGR5+ in CRC patients. a, b Kaplan–Meier analysis of the correlation between PIK3CA mutation and disease-free survival of 440 CRC patients from Jinan Military General Hospital. c Kaplan–Meier analysis of the correlation between PIK3CA mutation and overall survival of 440 CRC patients
Fig. 4 The prognostic value of PIK3CA mutation and LGR5+ in CRC patients. a, b Kaplan–Meier analysis of the correlation between PIK3CA mutation and disease-free survival of 440 CRC patients from Jinan Military General Hospital. c Kaplan–Meier analysis of the correlation between PIK3CA mutation and overall survival of 440 CRC patientsCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 55 references

Cited by

See all 147

Metadata

Authors
Wang, Q., Shi, Y.-L., Zhou, K., Wang, L.-L., Yan, Z.-X., Liu, Y.-L., Xu, L.-L., Zhao, S.-W., Chu, H.-L., Shi, T.-T., Ma, Q.-H., & Bi, J.
Affiliations
  • General Hospital of Jinan Military Command (CN)
  • Army Medical University (CN)
Corresponding author
Bi, Jingwang
Venue
Cell Death & Disease
Published
2018-07-03
Volume
9
Issue
7
Pages
739-739
ISSN
2041-4889 (ISSN-L)
OpenAlex
W2810475801
Cited by
147
References
55
Citations by year
2026: 14 · 2025: 20 · 2024: 21 · 2023: 16 · 2022: 16 · 2021: 26 · 2020: 21 · 2019: 13
FWCI
5.64
Type
journal article
Language
en
Open access
Licence
Locations
  • Cell Death and Disease (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
National Natural Science Foundation of China (81502283)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
Keywords
PIK3CA mutation, colorectal cancer, chemoresistance, first-line chemotherapy, PI3K/Akt signaling, Lgr5, colorectal cancer stem cells, predictive biomarkers, tumor stage, histological grade
MeSH terms
Adult, Aged, Aged, 80 and over, Cell Survival, Chromones, Female, Fluorouracil, Humans, Male, Middle Aged, Morpholines, Mutation, Phosphorylcholine, Retrospective Studies, Colorectal Neoplasms, Multivariate Analysis, Receptors, G-Protein-Coupled, HCT116 Cells, Class I Phosphatidylinositol 3-Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PIK3CA mutations confer resistance to first-line chemotherapy in colorectal cancer. https://app.cochat.ai/papers/10.1038/s41419-018-0776-6
The paper
Wang, Q., Shi, Y.-L., Zhou, K., Wang, L.-L., Yan, Z.-X., Liu, Y.-L., Xu, L.-L., Zhao, S.-W., Chu, H.-L., Shi, T.-T., Ma, Q.-H., & Bi, J. (2018). PIK3CA mutations confer resistance to first-line chemotherapy in colorectal cancer. Cell Death & Disease. https://doi.org/10.1038/s41419-018-0776-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.